Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645212 · ClinicalTrials.gov registry record
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
A clinical trial of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, sponsored by Adverum Biotechnologies.
- Active
- Registry status
- 23
- Enrollment target
- 9
- Study locations
NCT04645212 is a study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration that is active but no longer recruiting, run by Adverum Biotechnologies. The registered enrollment target is 23 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT04645212, a study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Adverum Biotechnologies.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 9
- Study locations
Study Summary
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
Conditions Studied
Interventions
- BIOLOGICAL ADVM-022
Study Locations (9)
California
- Adverum Clinical Site - Bakersfield
- Adverum Clinical Site - Beverly Hills
Texas
- Adverum Clinical Site - Bellaire
- Adverum Clinical Site - The Woodlands
Colorado
- Adverum Clinical Site - Lakewood
Florida
- Adverum Clinical Site - Deerfield Beach
Nevada
- Adverum Clinical Site - Reno
Pennsylvania
- Adverum Clinical Site - Philadelphia
Tennessee
- Adverum Clinical Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2030-06-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04645212
The ClinicalTrials.gov registry entry for NCT04645212 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which ADVM-022 is the first listed.
NCT04645212 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT04645212 about?
NCT04645212 is a clinical study titled "Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]". ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
What is the current status of trial NCT04645212?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2020-12-14. Estimated completion is 2030-06-26.
What conditions does trial NCT04645212 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT04645212?
The interventions under investigation include: ADVM-022 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04645212?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04645212 being conducted?
This trial has 9 study locations across California, Colorado, Florida, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
RECRUITING · Phase 4
Explore more on PlainTrial
Neovascular Age-related Macular Degeneration
All registered trials for this condition
Wet Age-related Macular Degeneration
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.